Abstract
Objective: to determine modifiable factors, personal, family, treatment, self-harm and health services associated with hospitalization in psychotic patients. Methods: analytical study of cases (hospitalized) and controls (not hospitalized), matched for psychiatric diagnosis, age, and gender, with a ratio of 1:2 case-control, psychotic patients were taken to the psychiatric care hospital: Clínica de Psiquiatrica in Bogotá during 2008- 2009. Previous informed consent, information was collected through interviews with the patient or caregiver in a questionnaire about modifiable factors for hospitalization of psychotic patients, personal factors, family, treatment, service use and self-injury and checked with the clinical systematized history of the institution and by telephone when necessary. Results: the average age of the group was 41.1 ± 12.2 years, the gender distribution was similar and the most frequent diagnosis was schizophrenia (54.3%), being similar between cases and controls. In the group of personal factors hospitalization (cases) was associated with low socioeconomic status (I-II) (OR = 2.37, 1.48,3.81), low educational level (OR = 1.95, 1.06,3.61), consuming legal and illegal psychoactive substances ( alcohol and cigarettes). Regarding disease variables, association was found with when patient does not recognize mental illness, younger age at diagnosis of mental illness, and when the patient's mother had a mental illness. In regard to access to treatment, protective factors were: to get on time all psychiatric medications delivery of all drugs in the last month and the last year by the mental health service (EPS, Spanish abbreviation), full compliance with prescribed drugs. Adverse events related to non-consumption of psychiatric drugs was significantly associated with hospitalization of psychotic patients. Regarding access to health services the failure of attending the psychiatric appointments in the past year, low frequency of psychiatric appointments in both the last year and in the last three months, and hospitalizations for mental illness were significantly higher in the patient group (7.12 ± 7.0, med = 5) than in the control group (3.9 ± 6.0, med = 2) (p <0.001). In the family and socialization factors, living alone, relationships only with relatives, and accompanying less frequent psychiatric appointments were found significantly associated. The suicide attempt was found significantly associated with hospitalization in psychotic patients (OR = 2.1, 95% CI: 1.28, 3.33, p = 0.003) and number of suicide attempts was significantly higher in the case group than in the controls (p = 0.003). Multiple conditional logistic regression showed associated to hospitalization low socioeconomic status (OR = 2.67, 95% CI: 1.29,5.52), living with relatives who have mental illness (OR = 4.71, 95% CI 1.39,16.07), frequency of previous psychiatric hospitalizations (> = 6 hospitalizations, OR = 7.55, 95% CI 3.03,18.85), high frequency to stop using drugs in the last month (> = 6 days, OR = 13.29, 95% CI 4.30,41.11), relationships only with members of their family (OR = 8.80, 95% CI 1.99,38.95), and some family members accompanying psychiatric consultations ( OR = 4.55, 95% CI 1.63,13.66). In addition frequency of attendance at psychiatric consultations in the past year (> = 11 citations, OR = 0,127 (0.045,0.353) was inversely associated to cases. Conclusions: the modifiable factors of personal (low income, low education, not to recognize his illness, his mother with psychiatric problems), limited access to treatment (not having the medication on time and in full), poor adherence to treatment (incomplete consumption of doses, stop taking drugs, and adverse
events), limited access to psychiatric services by the patient (and Infrequently breach appointments psychiatric care, frequent hospitalizations), family relationship problems and socialization ( living alone, accompanying the patient infrequently, poor relationships with people) and self-harm (suicide attempts) are associated with hospitalization in a psychotic patient.
References
Mason P, Harrison G, Glazebrook C, Medley I, Croudace T. The course of schizophrenia over 13 years. Br J Psychiatry 1996; 169:580-586. https://doi.org/10.1192/bjp.169.5.580
Shepherd M, Watt D, Falloon I, Smeeton N. The natural History of schizophrenia: A five year follow -up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med. Monogr Suppl 1989; 15:1-44. https://doi.org/10.1017/S026418010000059X
Watt D.C, Katz K, Shepherd M. The natural History of schizophrenia: a five-year prospective followup of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 1983; 13(3):663-670. https://doi.org/10.1017/S0033291700048091
Csernansky JG, Schuchart EK. Relapse and rehospitalization rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002; 16(7):473-484. https://doi.org/10.2165/00023210-200216070-00004
Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995 Sep;40 (7 Suppl 2):S60-7. https://doi.org/10.1177/070674379504007s06
Weiden J. Oltson M. Cost of relapse in Schizophrenia. Boletín de Esquizofrenia Instituto Nacional de Salud Mental 1995;21:3.
Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results, and implications. Am J Manag Care 1997; 3(6): 873-877.
Torres de Galvis Y, Montoya Bl. II estudio mental y consumo de sustancias psicoactivas. Colombia, 1997. Ministerio de salud. 1998.
Susuki Y, Yasumura S, Fukao A, Otani K. Associated factors of rehospitalization among schizophrenic patients. Psychiatry and Clinical Neurosciences 2003; Dec 57(6):555-561. https://doi.org/10.1046/j.1440-1819.2003.01167.x
Carr V, Patrick J, Johnston P, Terry J, Rajkumar S, Carter G, Issakidis C . Patterns of service use among persons with Schizophrenia and Other Psichotic Disorder. Psychiatric Services 2003; 54:226-235. https://doi.org/10.1176/appi.ps.54.2.226
Kent S, Yellowlees P. Psychiatric and social reasons for frequent rehospitalization. Hosp Community Psychiatry 1994 Apr;45(4):347-350. https://doi.org/10.1176/ps.45.4.347
Hoffmann H. Age and other factors relevant to the rehospitalization of schizophrenic outpatients. Acta Psychiatr Scand 1994 Mar; 89(3): 205-210. https://doi.org/10.1111/j.1600-0447.1994.tb08093.x
Postrado LT, Lehman AF. Quality of life and clinical predictors of rehospitalization of persons with severe mental illness. Psychiatr Serv 1995 Nov;46(11):1161-5. https://doi.org/10.1176/ps.46.11.1161
Buchkremer G, Stricker K, Holle R, Kuhs H. The predictability of relapses in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1991;240(4-5): 292-300. https://doi.org/10.1007/BF02189543
Doering S, Muller E, Kopcke W, Pietzcker A, Gaebel W, Linden M, Muller P, Muller-Spahn F, Tegeler J, Schussler G. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24(1):87-98. https://doi.org/10.1093/oxfordjournals.schbul.a033316
Faccincani C, Mignolli G, Platt S. Service utilisation, social support and psychiatric status in a cohort of patients with schizophrenic psychoses. A 7 year follow-up study. Schizophr Res 1990 MarApr;3(2):139-46. https://doi.org/10.1016/0920-9964(90)90047-B
Sullivan G, Young AS, Morgenstern H. Behaviors as risk factors for rehospitalization: implications for predicting and preventing admissions among the seriously mentally ill. Soc Psychiatry Psychiatr Epidemiol 1997 May;32(4):185-90. https://doi.org/10.1007/BF00788237
Valencia M, Saldivar G, Rivera E. [18-month followup of patients with schizophrenia.] Salud Pública Mex 1994 Nov-Dec;36(6):662-9.
Hale A. Will the new antipsychotics improve the treatment of schizophrenia?. BMJ 1993 Sep;307(6907):749-750. https://doi.org/10.1136/bmj.307.6907.749-a
Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003 Apr;54(4):508-16. https://doi.org/10.1176/appi.ps.54.4.508
Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002 Dec; 63(12):1121-8. https://doi.org/10.4088/JCP.v63n1206
Tamayo M. Marihuana y Esquizofrenia: ¿Un diagnóstico dual inocuo y terapéutico?. Vol. XXVII. Rev. Col. Psiquiatría 1998.
Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994 Nov;39(9 Suppl2):S65-9.
Alpont S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in Schizophrenia: costs, clinical outcomes and quality of life Br Psychiatry 2004 Apr; 184:346-51. https://doi.org/10.1192/bjp.184.4.346
Schlesselman J.J. Case-Control: Studies, Design, Conduct, Analysis. Nueva York: Oxford University Press; 1982.
Wacholder S, McLaughlin J K, Silverman D T, Mandel S M. Selection of controls in case - control studies: I principles. American Journal of Epidemiology 1992; 135: 1019-1028. https://doi.org/10.1093/oxfordjournals.aje.a116396
Wacholder S, Silverman D T, McLaughlin J K, Mandel S M. Selection of controls in case - control studies: II Types de control. American Journal of Epidemiology 1992; 135: 1019-1028. https://doi.org/10.1093/oxfordjournals.aje.a116396
Wacholder S, Silverman D T, McLaughlin J K, Mandel S M. Selection of controls in case - control studies: III Design options. American Journal of Epidemiology 1992; 135: 1042-1050. https://doi.org/10.1093/oxfordjournals.aje.a116398
Rothman K J. Epidemiologia Moderna. Madrid: Diaz de Santos; 1987.
Lachin J.M. Power and Sample Size Evaluation for the Mcnemar Test With Application to Mached Case-Control Studies. Statistics in Medicine. Vol. 11, 1239-1251;1992. https://doi.org/10.1002/sim.4780110909